[go: up one dir, main page]

DK2315765T3 - Faste former af (1R,2S,3R)-1-(2-isoxazol-3-yl)-1H-imidazol-4-yl)butan-1,2,3,4-tetraol samt fremgangsmåder til deres anvendelse - Google Patents

Faste former af (1R,2S,3R)-1-(2-isoxazol-3-yl)-1H-imidazol-4-yl)butan-1,2,3,4-tetraol samt fremgangsmåder til deres anvendelse

Info

Publication number
DK2315765T3
DK2315765T3 DK09744242.0T DK09744242T DK2315765T3 DK 2315765 T3 DK2315765 T3 DK 2315765T3 DK 09744242 T DK09744242 T DK 09744242T DK 2315765 T3 DK2315765 T3 DK 2315765T3
Authority
DK
Denmark
Prior art keywords
tetraol
isoxazol
imidazol
butane
methods
Prior art date
Application number
DK09744242.0T
Other languages
English (en)
Inventor
Hugh Alfred Burgoon
Suzanne Marie Buttar
Christopher Stephen Frampton
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Application granted granted Critical
Publication of DK2315765T3 publication Critical patent/DK2315765T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DK09744242.0T 2008-06-18 2009-06-16 Faste former af (1R,2S,3R)-1-(2-isoxazol-3-yl)-1H-imidazol-4-yl)butan-1,2,3,4-tetraol samt fremgangsmåder til deres anvendelse DK2315765T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7339808P 2008-06-18 2008-06-18
PCT/US2009/047488 WO2010008733A2 (en) 2008-06-18 2009-06-16 Solid forms of (1r,2s,3r)-1-(2-(isoxazol-3-yl)-1h-imidazol-4-yl)butane-1,2,3,4-tetraol and methods of their use

Publications (1)

Publication Number Publication Date
DK2315765T3 true DK2315765T3 (da) 2013-03-25

Family

ID=41381634

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09744242.0T DK2315765T3 (da) 2008-06-18 2009-06-16 Faste former af (1R,2S,3R)-1-(2-isoxazol-3-yl)-1H-imidazol-4-yl)butan-1,2,3,4-tetraol samt fremgangsmåder til deres anvendelse

Country Status (20)

Country Link
US (1) US7998994B2 (da)
EP (1) EP2315765B1 (da)
JP (1) JP5550644B2 (da)
KR (1) KR20110036582A (da)
CN (1) CN102131803A (da)
AR (1) AR072153A1 (da)
AU (1) AU2009271408A1 (da)
BR (1) BRPI0914167A2 (da)
CA (1) CA2728094A1 (da)
CL (1) CL2009001436A1 (da)
CO (1) CO6341474A2 (da)
DK (1) DK2315765T3 (da)
ES (1) ES2401555T3 (da)
IL (1) IL209815A0 (da)
MX (1) MX2010013991A (da)
PE (1) PE20100085A1 (da)
RU (1) RU2011101535A (da)
TW (1) TW201004943A (da)
UY (1) UY31900A (da)
WO (1) WO2010008733A2 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201002698A (en) * 2008-06-18 2010-01-16 Lexicon Pharmaceuticals Inc Methods of preparing imidazole-based bicyclic compounds
US8653126B2 (en) 2010-02-18 2014-02-18 Daiichi Sankyo Company, Limited Imidazole derivative
WO2012002274A1 (ja) 2010-06-28 2012-01-05 第一三共株式会社 培養細胞を用いたｓ１ｐリアーゼ阻害剤のスクリーニング方法
DE102011103751A1 (de) 2011-05-31 2012-12-06 Heraeus Precious Metals Gmbh & Co. Kg Kristallisierung von Epirubicinhydrochlorid
US9120835B2 (en) 2011-06-28 2015-09-01 Daiichi Sankyo Company Limited Phosphoric acid ester derivatives
EP2545922A1 (en) 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567194A (en) * 1983-03-10 1986-01-28 The Coca-Cola Company 2-Acylimidazole compounds, their synthesis and use as medicinal agents
DE4430289A1 (de) * 1993-09-04 1995-03-09 Basf Ag Verbessertes Verfahren zur Herstellung von Astaxanthin
AU2881797A (en) * 1996-05-31 1998-01-05 University Of Wollongong, The Acetyl derivatives of thiazoles and analogues
JPH1149972A (ja) * 1997-07-31 1999-02-23 Jiyun Internatl:Kk 殻廃棄物からアスタキサンチン及びキトーサンを同時に生成する方法
EP2266419A1 (en) * 2005-05-23 2010-12-29 Phares Drug Delivery AG Direct dissolution of carotenoids in edible oils and fats
CA2612592A1 (en) 2005-06-28 2007-01-04 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
ITMI20052486A1 (it) * 2005-12-23 2007-06-24 Italiana Sint Spa Procedimento di sintesi di intermedi per la preparazione di astaxantina
US7649098B2 (en) 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
TW200848029A (en) * 2007-03-01 2008-12-16 Lexicon Pharmaceuticals Inc Heterocyclic compounds, compositions comprising them and methods of their use
TWI412362B (zh) 2007-04-12 2013-10-21 Lexicon Pharmaceuticals Inc （ｅ）-１-（４-（（１ｒ，２ｓ，３ｒ）-１，２，３，４-四羥丁基）-１ｈ-咪唑-２-基）乙酮肟的固體形式
TW201002698A (en) 2008-06-18 2010-01-16 Lexicon Pharmaceuticals Inc Methods of preparing imidazole-based bicyclic compounds
EP2346504A1 (en) * 2008-08-22 2011-07-27 Lexicon Pharmaceuticals, Inc. Combinations comprising bicyclic s1p lyase inhibitors

Also Published As

Publication number Publication date
CO6341474A2 (es) 2011-11-21
WO2010008733A2 (en) 2010-01-21
PE20100085A1 (es) 2010-02-05
MX2010013991A (es) 2011-01-14
TW201004943A (en) 2010-02-01
RU2011101535A (ru) 2012-07-27
US7998994B2 (en) 2011-08-16
WO2010008733A3 (en) 2010-03-25
US20090318516A1 (en) 2009-12-24
IL209815A0 (en) 2011-02-28
AU2009271408A1 (en) 2010-01-21
UY31900A (es) 2010-01-29
BRPI0914167A2 (pt) 2015-10-20
CN102131803A (zh) 2011-07-20
JP5550644B2 (ja) 2014-07-16
KR20110036582A (ko) 2011-04-07
CA2728094A1 (en) 2010-01-21
ES2401555T3 (es) 2013-04-22
EP2315765B1 (en) 2012-12-19
AR072153A1 (es) 2010-08-11
EP2315765A2 (en) 2011-05-04
JP2011524915A (ja) 2011-09-08
CL2009001436A1 (es) 2010-10-01

Similar Documents

Publication Publication Date Title
CY2019009I2 (el) Αναστολεις πρωτεϊνικων κινασων
BRPI0914217A2 (pt) Compostos de amida piridil-pirazolil 1-substituída e usos dos mesmos
WO2009117421A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
DK2300443T3 (da) Triazolderivater, der er anvendelige til behandling af sygdomme
PL3835297T3 (pl) Synteza i związki pośrednie (r)-1-(2,2-difluorobenzo[d][1,3]-dioksol-5-ilo)-n-(1-(2,3-dihydroksypropylo)-6-fluoro-2-(1-hydroksy-2-metylopropan-2-ylo)-1h-indol-5-ilo)-cyklopropanokarboksyamidu
BRPI0922043A2 (pt) composições compreendendo um aril pirazol e/ou formamidina, métodos e usos das mesmas
EA201170227A1 (ru) Имидазолкарбоксамиды
BRPI0714291A2 (pt) Derivados de [4,5']bipirimidinil-6-4'-diamina como inibidores de proteína cinase
EP2332943A4 (en) NOVEL CONDENSATE AMINODIHYDROTHIAZINE DERIVATIVE
ES2590905T8 (es) Inhibidores de la tirosina quinasa de Bruton
BRPI0910668A2 (pt) inibidores de proteína quinases
EP2244670A4 (en) INTERSPINED DISTANCE MEMBER
IT1395237B1 (it) Procedimento per la connessione di parti di autotelaio e gruppi strutturali di autotelaio.
DK2315765T3 (da) Faste former af (1R,2S,3R)-1-(2-isoxazol-3-yl)-1H-imidazol-4-yl)butan-1,2,3,4-tetraol samt fremgangsmåder til deres anvendelse
DK2389378T3 (da) Fremgangsmåde og terapeutisk anvendelse af (2s,3r)-n-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorbenzamid
DK2315750T3 (da) Forbedret fremgangsmåde til fremstilling af 2-trifluormethyl-5-(1-substituerede) alkylpyridiner
WO2009089234A3 (en) Substituted dibenzhydrylpiperazines
DK2370918T3 (da) Multimedie-identifikator
DK2296473T3 (da) Virksomt 4-(3-alkylsulfinylbenzoyl) pyrazol-herbicid
EP2229213A4 (en) CARDIAC COMPRESSION SYSTEM
DK2462098T3 (da) Fremgangsmåde til fremstillingen af derivater af 1-(2-halobiphenyl-4-yl)-cyclopropancarboxylsyre
FI20086108L (fi) Halkaisukiila
BR112014009308A2 (pt) formas de dosagem sólida de 2-amino-3-(4-(2-amino-6-((r)-1-(4-cloro-2-(3-metil-1h-pirazol-1-il)fenil)-2,2,2-trifloroetóxi) pirimidin-4-il)fenil) propanoato de (s)-etila
BRPI0817010A2 (pt) Processo de preparação de um composto p-hidroximandélico eventualmente substituído e derivado e de um aldeído 4-hidroxiaromático.
IL201037A0 (en) Solid forms of (e)-1-(4-(1r,2s,3r)-1,2,3,4-tetrahydroxybutyl)-1h-imidazol-2-yl)ethanone oxime